Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone : Analysis of the Austrian head and neck cancer registry of the AGMT
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1613-7671
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone ; volume:133 ; number:21-22 ; day:15 ; month:9 ; year:2021 ; pages:1131-1136 ; date:11.2021
Wiener klinische Wochenschrift ; 133, Heft 21-22 (15.9.2021), 1131-1136, 11.2021
- Urheber
-
Magnes, Teresa
Wagner, Sandro M.
Melchardt, Thomas
Weiss, Lukas
Rinnerthaler, Gabriel
Huemer, Florian
Kopp, Michael
Gampenrieder, Simon Peter
Mayrbäurl, Beate
Füreder, Thorsten
Lenger, Daniel
Andel, Johannes
Egle, Alexander
Greil, Richard
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00508-021-01939-3
- URN
-
urn:nbn:de:101:1-2022012718230896803260
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Magnes, Teresa
- Wagner, Sandro M.
- Melchardt, Thomas
- Weiss, Lukas
- Rinnerthaler, Gabriel
- Huemer, Florian
- Kopp, Michael
- Gampenrieder, Simon Peter
- Mayrbäurl, Beate
- Füreder, Thorsten
- Lenger, Daniel
- Andel, Johannes
- Egle, Alexander
- Greil, Richard
- SpringerLink (Online service)
Ähnliche Objekte (12)
Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
Impact of cetuximab plus cisplatin alone and cetuximab plus cisplatin and paclitaxel regimen on humanistic outcome in head and neck cancer
Comparing cisplatin-Chemoradiotherapy to Cetuximab-radiotherapy in HPV+ “low-risk” locally advanced oropharyngeal squamous cell carcinoma: lessons from De-escalate study
Comparison of vinorelbine with cisplatin in concomitant chemoradiotherapy in head and neck carcinoma
Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control study
Efficacy of concurrent chemoradiotherapy with retrograde super selective intra-arterial infusion combined with cetuximab for synchronous multifocal oral squamous cell carcinomas
Primary chemoradiation with cisplatin versus cetuximab for locally advanced head and neck cancer: a retrospective cohort study
Weekly versus triweekly cisplatin treatment in patients with locally advanced nasopharyngeal cancer during concurrent chemoradiotherapy
Recapitulating the Pharmacological Interactions of Cetuximab with Sunitinib and Cisplatin in Head and Neck Carcinoma Cells in vitro
Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis
Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer
Concurrent chemoradiotherapy with conventional fractionated radiotherapy and low-dose daily cisplatin plus weekly docetaxel for T2N0 glottic cancer
Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
Impact of cetuximab plus cisplatin alone and cetuximab plus cisplatin and paclitaxel regimen on humanistic outcome in head and neck cancer
Comparing cisplatin-Chemoradiotherapy to Cetuximab-radiotherapy in HPV+ “low-risk” locally advanced oropharyngeal squamous cell carcinoma: lessons from De-escalate study
Comparison of vinorelbine with cisplatin in concomitant chemoradiotherapy in head and neck carcinoma
Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control study
Efficacy of concurrent chemoradiotherapy with retrograde super selective intra-arterial infusion combined with cetuximab for synchronous multifocal oral squamous cell carcinomas
Primary chemoradiation with cisplatin versus cetuximab for locally advanced head and neck cancer: a retrospective cohort study
Weekly versus triweekly cisplatin treatment in patients with locally advanced nasopharyngeal cancer during concurrent chemoradiotherapy
Recapitulating the Pharmacological Interactions of Cetuximab with Sunitinib and Cisplatin in Head and Neck Carcinoma Cells in vitro
Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis
Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer
Concurrent chemoradiotherapy with conventional fractionated radiotherapy and low-dose daily cisplatin plus weekly docetaxel for T2N0 glottic cancer
Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
Impact of cetuximab plus cisplatin alone and cetuximab plus cisplatin and paclitaxel regimen on humanistic outcome in head and neck cancer
Comparing cisplatin-Chemoradiotherapy to Cetuximab-radiotherapy in HPV+ “low-risk” locally advanced oropharyngeal squamous cell carcinoma: lessons from De-escalate study
Comparison of vinorelbine with cisplatin in concomitant chemoradiotherapy in head and neck carcinoma
Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control study
Efficacy of concurrent chemoradiotherapy with retrograde super selective intra-arterial infusion combined with cetuximab for synchronous multifocal oral squamous cell carcinomas
Primary chemoradiation with cisplatin versus cetuximab for locally advanced head and neck cancer: a retrospective cohort study
Weekly versus triweekly cisplatin treatment in patients with locally advanced nasopharyngeal cancer during concurrent chemoradiotherapy
Recapitulating the Pharmacological Interactions of Cetuximab with Sunitinib and Cisplatin in Head and Neck Carcinoma Cells in vitro
Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis
Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer